BRAF and melanoma: Supporting the efficacy of the BRAF inhibitor against BRAF(V600E)-mutant melanoma, a recent study suggested that BRAF inhibition directly enhanced NK cells’ immunostimulatory capacity via upregulating CD69 expression and IFNR release [60].